GGrantIndex
Sort

10,766 grants matching checkpoint inhibitor

Project 4: Therapeutic Targeting of Replication Stress Vulnerabilities in Small Cell Lung Cancer

$463,389
Lauren Averett Byers · Ut Southwestern Medical Center · P50 · FY2021 · CA

Mechanisms of cell death in cutaneous melanoma

$463,189
Andrew E Aplin · Thomas Jefferson University · R01 · FY2022 · CA

Targeting apoptotic caspases to enhance cancer radiotherapy

$463,156
Chuan-Yuan Li · Duke University · R01 · FY2018 · CA

Project 3: Chemotherapy and Immunotherapy Biomarker Development for Triple Negative Breast Cancer

$463,085
Charles M Perou · Univ Of North Carolina Chapel Hill · P50 · FY2020 · CA

Developing BRAF mutant and BRAF wild-type selective strategies for radiosensitization in Anaplastic Thyroid Cancer

$462,998
Terence Marques Williams · Beckman Research Institute/City Of Hope · R01 · FY2025 · CA

Metastatic Clonal Heterogeneity and its Impact on Melanoma Therapeutic Resistance

$462,960
Willy Hugo · University Of California Los Angeles · R01 · FY2022 · CA

Metastatic Clonal Heterogeneity and its Impact on Melanoma Therapeutic Resistance

$462,960
Willy Hugo · University Of California Los Angeles · R01 · FY2021 · CA

Vascular image-guided optimization of response (VIGOR) to therapy in kidney cancer

$462,812
Li Liu · Ut Southwestern Medical Center · R01 · FY2024 · CA

Decoding tobacco-related oral cancer ecosystem by integrative approach

$462,811
Aik Choon Tan · University Of Utah · R01 · FY2022 · DE

An Environmental Chemical Receptor, the AhR, as a Mediator of Multiple Immune Checkpoints in Oral Cancer

$462,785
David H Sherr · Boston University Medical Campus · R01 · FY2022 · ES

Chitinase-3-like-1 mediated immunosuppression in Glioblastoma

$462,773
Baoli Hu · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · CA

Stroma penetrating and immune modulating nanoparticles for image-guided therapy of pancreatic cancer

$462,770
Lily Yang · Emory University · R01 · FY2023 · CA

Stroma penetrating and immune modulating nanoparticles for image-guided therapy of pancreatic cancer

$462,770
Lily Yang · Emory University · R01 · FY2022 · CA

Targeting the EGFR-PI3K/mTOR Signaling Circuitry: A Network-Based Approach for Oral Cancer Precision Therapy

$462,426
J. Silvio Gutkind · University Of California, San Diego · R01 · FY2022 · DE

Defining and Targeting Homologous Recombination Deficiency in Breast Cancer

$462,413
Simon N Powell · Sloan-Kettering Inst Can Research · P50 · FY2020 · CA

Systematic, molecular level analysis of the Fc receptor ligation on antibody effector functions

$462,410
George Georgiou Georgiou · University Of Texas At Austin · U01 · FY2021 · AI

Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer

$462,269
Donald W. Kufe · Dana-Farber Cancer Inst · R01 · FY2025 · CA

Targeting Posttranslational Modifications in Breast Carcinogenesis

$462,243
Yong Wan · Emory University · R01 · FY2022 · CA

Investigating novel targets for topical immunoprevention of keratinocytic skin cancer

$462,092
Sally E Dickinson · University Of Arizona · UG3 · FY2025 · CA

HSP70 and melanoma

$462,002
Maureen E Murphy · Wistar Institute · R01 · FY2015 · CA

A New Mode of Inhibition to Target Protein-Protein Interactions by Ligand-Transferred Oxidation

$462,000
Juan Pablo Maianti · Albert Einstein College Of Medicine · R35 · FY2025 · GM

Systematic, molecular level analysis of the Fc receptor ligation on antibody effector functions

$461,998
George Georgiou Georgiou · University Of Texas At Austin · U01 · FY2022 · AI

Macrophages as modulators of T cell function and therapeutic response in clear cell renal cell carcinoma

$461,996
Abraham Ari Hakimi · Sloan-Kettering Inst Can Research · R01 · FY2024 · CA

DNA damage response and cancer immunity

$461,897
Christopher J. Bakkenist · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · CA

DNA damage response and cancer immunity

$461,897
Christopher J. Bakkenist · University Of Pittsburgh At Pittsburgh · R01 · FY2022 · CA